Attendees

POST EVENT REPORT

Organisations

Experts Speakers

ATTENDEE BREAKDOWN

By Seniority

By Country

TESTIMONIALS

Dennis Stelljes | Associate Director, Strategic Sourcing & Procurement, Biologics External Manufacturing, BMS, Switzerland

"Just back from an incredible time at the Biologics Manufacturing DACH congress! I have to be honest - as someone in Procurement, some of the deep-dives into Cell & Gene and biologics development were definitely above my scientific capabilities! However, the exchange of knowledge was fantastic, and it was a privilege to learn from such brilliant minds. A true highlight was the fantastic collaboration with Christopher Pawlak (PhD) . I had the privilege of co-hosting a round table with him focused on the impact of tariffs in the biopharma world. Christoph, thank you for the partnership - it was a truly dynamic discussion! 🤝 One of my biggest takeaways is that we have officially entered the era of "The Great Reshoring". We are moving past the days when drug manufacturing decisions were purely scientific; they are now deeply geopolitical. As we discussed in our round table, we can no longer just react to change. We have to treat scenario planning like a muscle that we train constantly to design for volatility. The event really hit home how much our world is changing - from the incredible progress in biologics manufacturing to the AI evolution. I’m excited to see how we can implement these insights to build resilience and benefit BMS biologics manufacturing. Back to my desk, I will start with socializing the learnings with my colleagues. A huge thank you to Drishti G. for the flawless organization and to Noel Murphy for approving the trip and supporting this critical learning opportunity!"

Dr Heiner Apeler | VP Head of Biologics Development Bayer, Germany

"The Biologics and CGT Manufacturing DACH conference 2026 was very well planned and coordinated. It provided high-quality talks for staying up-to-date in our industry and I specifically enjoyed the time for networking."

John Bridgeman | CSO, Immunokey, UK

"Thanks for the invite to speak at the event. It was a really enjoyable meeting and a great opportunity to present our work to the community. Identifying key partners for ImmunoKey’s development plan is a critical aspect of getting our therapies to patients; the CGT and Biologics Manufacturing DACH meeting offered us the opportunity to engage with key CDMOs who can help us achieve this goal."

Dr Andrew Kelly | Director, Manufacturing Technology, BMS, Ireland

"Really well organised conference with great attendees and high engagement - I was delighted to have taken the time to attend and really enjoyed sharing my thoughts on Accelerating Biologics Pipeline and ensuing discussion. Thank you to all organisers and facilitators."

Dr Thomas Villiger | Professor of Bioprocess Technology, University of Applied Sciences and Arts Northwestern Switzerland FHNW, Switzerland

"A fantastic deep dive into the DACH region’s CGT landscape. This conference made one thing clear: efficacy is proven, but industrialization is the new frontier. To truly move the needle, we must look beyond the lab and focus on scaling automation, streamlining supply chains, and tackling COGS. The diversity of voices - from large corporations, to tech suppliers and academic pioneers - provided a 360-degree view of the manufacturing challenges we must solve together."

Brian O'Connor | VP Global Quality, Orchard Therapeutics, UK

"Thanks for the invite. The conference was really excellent, due to the caliber and engagement of the attendees."

Alvaro Avivar-Valderas | Associate Director - Cell Therapy Technology & Product Engine, Takeda, Spain

"Thanks for putting this together! I enjoyed the discussions, atmosphere and engagement of participants. Great to be there!"

Steffen Schulze | Strategic Analytics & Business Analytics Lead, Roche, Switzerland

"I thoroughly enjoyed attending the CGT Manufacturing DACH 2026 by IMAPAC. The program featured exceptionally industry-relevant talks that provided deep insights into the current landscape. Beyond the sessions, the networking opportunities were top-tier, thanks to the high caliber of participants."